linjc16/ctgov huggingface dataset:
A Registry of De Winter Symdrome of Single Center

Study Overview
=================
Brief Summary
-----------------
This registry started January 1,2018 to collect patients who diagnosed as De Winter Symdrome for the first time in Hainan General Hospital.All enrolled patients will receive 30 days followed-up.

Official Title
-----------------
A Registry of De Winter Symdrome of Hainan General Hospital

Conditions
-----------------
ACS - Acute Coronary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Index ECG ST segment showed a 1- to 3-mm upsloping ST-segment depression at the J point in leads V1 to V6 that continued into tall, positive symmetrical T waves Received coronary angiography during hospitalization Exclusion Criteria: -No coronary angiography results was available during hospitalization

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| DeWinterCohort<br>Patients with de Winter syndrome pattern ECG | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with MACEs within 30 days | Number of participants with cardiac death,non-fatal myocardial infarction,stroke,heart failure in 30 days | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with MACEs In-hospital | Number of participants with cardiac death,non-fatal myocardial infarction,stroke,heart failure in-hospital | throughout current hospitalization | 
| Number of Participants with MACEs within 7 days after admitted | Number of participants with cardiac death,non-fatal myocardial infarction,stroke,heart failure in 7 days | 7 days after admitted | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
De Winter Syndrome
Effect of Gastric Balloon in Morbid Obesity: Prospective Study

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the efficacy of gastric balloon in weight reduction among two different categories of morbidly obese people.

Detailed Description
-----------------
To study to effect of gastric balloon in weight reduction among those above 35 BMI and those above 45 BMI.

Official Title
-----------------
Effect of Gastric Balloon in Morbid Obesity: Prospective Study

Conditions
-----------------
Morbid Obesity

Intervention / Treatment
-----------------
* Device: BMI more than 45 BMI
* Device: BMI less than 45 BMI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: morbid obesity Exclusion Criteria: patient refusal psychological patients oesophageal or gastric abnormalities
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: BMI more than 45 BMI<br>Air filled gastric balloon (Heliosphere) those BMI above 45 | Device: BMI more than 45 BMI<br>* Air filled gastric balloon (Heliosphere) those BMI above 45<br>|
| Active Comparator: BMI less than 45 BMI<br>Air filled gastric balloon (Heliosphere)those BMI below 45 | Device: BMI less than 45 BMI<br>* Air filled gastric balloon (Heliosphere) those BMI below 45<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of weight loss | By following up the BMI every month | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerance | Tolerance of patients to the balloon in form of vomiting, nausea, gastric pain | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastric balloon, morbid obesity
Association Between Confocal Laser Endomicroscopic (CLE) Features and Colorectal Mucosal Microbiome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether an association between endomicroscopic pattern and colorectal mucosal microbiome exists.

Detailed Description
-----------------
The gut microbiome plays a pivotal role in the intestinal pathophysiology. The mucosal microbiome is in the front face of microbiome-host cross-talk. Confocal laser endomicroscopy (CLE) can provide realtime mucosal images during ongoing endoscopy. We hypothesized that the mucosal pattern, here evaluated by endomicroscopy, may constitute specific microbiome niches and participate the evolvement of the mucosal microbiome.

Official Title
-----------------
Association Between Confocal Laser Endomicroscopic (CLE) Features and Colorectal Mucosal Microbiome

Conditions
-----------------
Colorectal Neoplasia, Colorectal Inflammation, Hyperplasia, Mucosal Microbiome

Intervention / Treatment
-----------------
* Other: the mucosal microbiome in the biopsy specimen was analysed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old ≤ age < 80 years old Scheduled for colonoscopy in Qilu Hospital Exclusion Criteria: antibiotic usage within 2 months probiotic or prebiotic usage within 2 months ascites jaundice liver cirrhosis impaired renal function coagulopathy fever pregnancy breastfeeding inability to provide informed consent known allergy to fluorescein sodium

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| endomicroscopy<br> | Other: the mucosal microbiome in the biopsy specimen was analysed<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The operational taxonomy unit in the colorectal mucosal microbiome. |  | 6 months |
Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Colonosopy

Study Overview
=================
Brief Summary
-----------------
Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Detailed Description
-----------------
Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Official Title
-----------------
Randomised Study Comparing the Use of Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Conditions
-----------------
Colonic Diseases

Intervention / Treatment
-----------------
* Drug: Propofol
* Drug: Dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 25-45 years, ASA class I or II, who are scheduled for elective outpatient colonoscopy Exclusion Criteria: refused to give informed consent if they had known hypersensitivity to the used drugs patients with morbidly obese patients patients with increased risk for airway obstruction as obstructive sleep apnea, Liver diseases

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: • Propofol Group<br>propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.. | Drug: Propofol<br>* propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.<br>|
| Active Comparator: • Dexmedetomidine Group<br>dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure | Drug: Dexmedetomidine<br>* dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with adequate sedation | the number of patients adequately sedated | 6 months |
A Health Action Process Approach Online Intervention for People With Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to implement the person-centered internet-based Health Action Process Approach to promoting physical activity in people with Multiple Sclerosis (i.e., eHAPA-MS online intervention) and assess the intervention's effectiveness and adherence.

Official Title
-----------------
Developing A Person-centered Internet-based Health Action Process Approach to Promoting Physical Activity in People With Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Behavioral: MSPA eClass


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: are 18 years old and above; have not maintained 30 minutes of MVPA accumulated per day for 2 days of the week during the previous 6 months; have a score < 24 for the leisure score index of the Godin Leisure-Time Exercise Questionnaire; be relapse-free for the past 30 days; show low risk for contraindications of PA indicated by no more than a single 'yes' response on the Physical Activity Readiness Questionnaire; be able to walk with or without an assistive device; are willing to be randomized to an intervention or control group, complete the surveys and questionnaires, and wear an accelerometer during the intervention period; have Internet access. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MSPA eClass<br> | Behavioral: MSPA eClass<br>* An 8-week MS-HAPA Internet-based intervention<br>|
| No Intervention: Waiting list<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Health Action Process Approach Battery | The battery measures risk perception, exercise benefits, motivation, and volition. change is being assessed. | Through study completion, an average of 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Physical Activity, Internet-Based Intervention
Vitamin D AND Glucose Handling Evaluated by Glucose Clamp

Study Overview
=================
Brief Summary
-----------------
In this study the investigators want to compare glucose handling (insulin secretion and insulin sensitivity) in 100 persons with low and 50 persons with normal-high levels of vitamin D, using a hyperglycemic clamp technique, were sugar is given intravenously for 3 hours in order to keep the blood sugar level at 10 mmol/L. Those with low vitamin D levels will be randomized to treatment with vitamin D3 (cholecalciferol) 40 000 IU/week or placebo for 6 months before a new clamp is performed. The study hypothesis is that persons with low vitamin D levels have impaired glucose handling which might be improved by vitamin D supplementation.

Official Title
-----------------
Vitamin D AND Cardiovascular Disease

Conditions
-----------------
Insulin Sensitivity, Intraocular Pressure

Intervention / Treatment
-----------------
* Drug: cholecalciferol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: generally: Subjects are recruited from the 6th Tromsø Study cases: serum 25-hydroxyvitamin D-levels below the 10 percentile; low levels confirmed with new serum analyses. controls: serum 25-hydroxyvitamin D levels 80-95 percentile, normal-high levels confirmed with new serum analyses. Exclusion Criteria: diabetes myocardial infarction or apoplexia active cancer during last 5 years history of kidney stone pregnancy or premenopausal without safe anticonception primary hyperparathyroidism systolic blood pressure >175 or diastolic blood pressure >105

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin secretion and sensitivity as assessed by an hyperglycemic clamp |  | 6 months | 
| intraocular pressure |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| telomer length |  | 6 months | 
| 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D-levels |  | 6 months | 
| serum calcium, PTH, phosphate |  | 6 months | 
| inflammatory markers and lipids |  | 6 months |
Digital Assessment of Mandibular Flexure in Full Arch Fixed Restorations

Study Overview
=================
Brief Summary
-----------------
Nine patients (five males and four females) were included in this study who had long-term (10-15 years) of long-span rigid mandibular fixed prostheses that may have led to radiographic changes around the supporting teeth. The treatment plans included the removal of the long-span fixed rigid prostheses followed by restoring the patients with segmented implant-supported prostheses. In order to digitally measure the mandibular flexure, reference markers were adhered to the prostheses, and intraoral scans were obtained before and after splitting the preexisting prostheses at the minimum and maximum mouth opening. The distances between the markers were measured, and mandibular flexure was calculated by subtracting the distance between the markers during the maximum mouth opening from the minimum mouth opening. An independent sample T-test was used to compare mandibular flexure before and after splitting the long-span fixed prostheses.

Official Title
-----------------
Retrospective Digital Study of Mandibular Flexure in Patients With Long-span Fixed Restorations Supported by Natural Teeth.

Conditions
-----------------
Mandibular Flexure, Full Arch Fixed Prosthesis

Intervention / Treatment
-----------------
* Procedure: Sectioning of the full arch mandibular fixed prosthesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: full-arch mandibular single fixed prostheses that served for many years (average 12 years) opposed by natural dentition. Patients were free from any systemic or debilitating diseases such as bone diseases, diabetes melilites, or blood dyscrasias. Exclusion Criteria: patients with healthy fixed full-arch prosthesis patients with segmented prosthesis patients with systematic debilitating diseases. Patients with temporomandibular joint dysfunction, maxillofacial surgeries, or mandibular trauma.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mandibular flexure before sectioning of full arch fixed prosthesis<br> | |
| Mandibular flexure after sectioning of full arch fixed prosthesis<br> | Procedure: Sectioning of the full arch mandibular fixed prosthesis<br>* The one unit full arch fixed prosthesis is sectioned at the midline into two pieces<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in mandibular flexure | change in mandibular flexure before and after splitting of the fixed full arch prosthesis | immediately after the splitting of the full arch fixed prosthesis. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mandibular flexure, Prosthesis Failure, Full arch restorations
Effects of Non-invasive Brain Stimulation in Impulse Control Disorders

Study Overview
=================
Brief Summary
-----------------
The goal of this project is to study the effect of noninvasive brain stimulation on decision-making and on brain activity in impulse control disorders.

Official Title
-----------------
Effects of Non-invasive Brain on Decision-making in Impulse Control Disorders

Conditions
-----------------
Impulse Control Disorder

Intervention / Treatment
-----------------
* Device: Noninvasive brain stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Impulse control disorders according to DSM-IV criteria Exclusion Criteria: Other psychiatric disorders Contraindication to Non-invasive brain stimulation and MRI

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Noninvasive brain stimulation: active<br>In active condition, subject will receive stimulation during all the 30-minute stimulation period | Device: Noninvasive brain stimulation<br> <br> |
| Sham Comparator: Noninvasive brain: sham<br>In sham condition, subject will receive stimulation only at the beginning and at the end of 30-minute stimulation period. | Device: Noninvasive brain stimulation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in decision-making from pre to post stimulation assessed with the Balloon Analogue Risk Task |  | 10 minutes before and immediately after the 30 minutes of non invasive brain stimulation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in brain activity assessed between before and during stimulation measured with functional magnetic resonance (fMRI) |  | 20 minutes before and immediately after the 30 minutes of non invasive brain stimulation | 
| Neural metabolites concentrations measured with magnetic resonance spectroscopy (MRS) |  | 20 minutes before and immediately after the 30 minutes of non invasive brain stimulation | 
| Change in Craving from pre to post stimulation assessed with a single standardized scale |  | 7 minutes before and 3 minutes after the end of the 30 minutes of non invasive brain stimulation |
Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction in Vietnamese HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
This study is to investigate clinical utility of beta2 microglobulin as an early marker for renal dysfunction caused by Tenofovir in Vietnamese HIV-infected patients.

Detailed Description
-----------------
An observational study to investigate clinical utility of beta2 microglobulin as an early marker for renal dysfunction caused by Tenofovir in Vietnamese HIV-infected patients.

Official Title
-----------------
Vietnam-Japan Cooperative Research on Prognosis of HIV-1-infection -Clinical Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction Caused by Use of Tenofovir in Vietnamese HIV-Infected Patients-

Conditions
-----------------
HIV Infection, Renal Function Disorder, Renal Tubular Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV-infected patients in the NHTD -ACC cohort who are under cART or will start cART and can provide written informed consents. Exclusion Criteria: HIV-infected patients who drop out of treatment within 6 months from the entry.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of urinary beta2microglobulin, urinary protein and serum creatinine among Vietnamese HIV-infected patients | Follow up Vietnamese HIV-infected patients, for their renal function including urinary beta2microglobulin, urinary protein and serum creatinine for 3 years | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of risk factors for renal dysfunction and tubular dysfunction | Risk factors for renal and tubular dysfunction were evaluated. Risk factors including: Age, sex, body weight, history of ART, AIDS or non-AIDS complication and concomitant use of cotrimoxazole, Hepatitis C virus antibody and Hepatitis B virus Ag antigen, CD4 positive cell count and HIV viral load. | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TDF:Tenofovir, Urine beta2microglobulin